Screener
Zevra Therapeutics, Inc. ZVRA Cash Paid To Settle Derivative Instrument and Payoff Premium
Cash Paid To Settle Derivative Instrument and Payoff Premium at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept zvra:CashPaidToSettleDerivativeInstrumentAndPayoffPremium.
The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026. Open the filing →
- Filed
- May 6, 2026, 5:14 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001434647-26-000031
FAQ
- What is Zevra Therapeutics, Inc.'s cash paid to settle derivative instrument and payoff premium?
- Zevra Therapeutics, Inc. (ZVRA) reported cash paid to settle derivative instrument and payoff premium of $9.02M in Q1 2026.
- What does cash paid to settle derivative instrument and payoff premium mean?
- Cash Paid To Settle Derivative Instrument and Payoff Premium as reported by Zevra Therapeutics, Inc. Common Stock.
Ask your AI about Zevra Therapeutics, Inc.'s cash paid to settle derivative instrument and payoff premium.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude